| 000 | 01759cam a2200277 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031023.0 | ||
| 008 | 140810s2013 ua o f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.34.M.Sc.2013.Am.M | ||
| 100 | 0 | _aAmro Hefnawy Mohamed Hefnawy | |
| 245 | 1 | 0 |
_aModulating celecoxib activity towards phosphodiesterase 5 inhibition rather than cyclooxygenase inhibition and evaluating its correlation to anticancer activity / _cAmro Hefnawy Mohamed Hefnawy ; Supervised Ashraf H. Abadi |
| 246 | 1 | 5 | _aتحوير نشاط السيليكوكسيب باتجاه تثبيط الفوسفودايستراز ٥ بدلا من انزيمات الأكسدة الحلقية و ارتباط ذلك بالنشاط المضاد للسرطان |
| 260 |
_aCairo : _bAmro Hefnawy Mohamed Hefnawy , _c2013 |
||
| 300 |
_a95 Leaves : _bphotographs ; _c30cm |
||
| 502 | _aThesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceutical Chemistry | ||
| 520 | _aSelective COX-2 inhibitors were introduced as safer alternatives to NSAIDs with less gastrointestinal side effects. Celecoxib, Rofecoxib and valdecoxib were the most widely used COX-2 inhibitors. Unfortunately, it was found that the use of selective COX-2 inhibitors is associated with increased cardiovascular risk. By 2011, celecoxib was the only selective COX-2 inhibitors to remain available in the market as it showed better cardiovascular safety | ||
| 700 | 0 |
_aAshraf Mustafa Kamal Hassan Abadi , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c46792 _d46792 |
||